Oak Street: Blueprint Medicines : Completes Acquisition of Lengo Therapeutics - Form 8-K

(marketscreener.com) Blueprint Medicines Completes Acquisition of Lengo Therapeutics -- Expands Blueprint Medicines' lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations -- Investigational New Drug application for LNG-451 submitted to U.S. FDA by...https://www.marketscreener.com/quote/stock/BLUEPRINT-MEDICINES-CORPO-22033569/news/Blueprint-Medicines-Completes-Acquisition-of-Lengo-Therapeutics-Form-8-K-37441427/?utm_medium=RSS&utm_content=20211230